Adela Popi is a PhD student on the MRC DTP iCASE Programme in the Rahman Lab, in partnership with AstraZeneca. She holds an MSci in Molecular and Cell Biology and Synthetic Organic Chemistry from University College London, where she was awarded a Dean’s List distinction. During her master’s, she worked on the molecular pharmacology of a novel ADC targeting solid tumours.
Her project focuses on targeted protein degraders (PROTACs), using the Collateral-ID platform to map off-target effects. She integrates chemical synthesis, proximity-labelling approaches, and cell-based studies to improve understanding of degrader selectivity. She is particularly interested in chemical biology approaches to cancer therapeutics.